A review of the efficacy of rosuvastatin in patients with type 2 diabetes

International Journal of Clinical Practice, Supplement

Volumn , Issue 143, 2004, Pages 30-40

  Tuomilehto, J ^a   Leiter, L A ^b   Kallend, D ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NONE

Author keywords

Cardiovascular disease; Diabetic dyslipidaemia; Rosuvastatin; Statins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; PYRIMIDINES; SULFONAMIDES;

EID: 10344222092     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (98)

1. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100-7.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-44.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
4. De Backer G, Ambrosioni E, Borch-Johnsen K et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.
5. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979; 2: 120-6.
6. (UKPDS 33). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
7. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-8.
8. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003; 5 (Suppl. 1): S19-27.
9. Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes, estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001; 24: 197-201.
10. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
11. Vijan S, Hayward RA; American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004; 140: 650-8.
12. Berne C, Siewert-Delle A. on behalf of the URANUS study investigators. Use of rosuvastatin versus atorvastatin in type 2 diabetes mellitus subjects: results of the URANUS study. 74th European Atherosclerosis Society Congress. Atherosclerosis 2004; 5 (Suppl 1): 107, (Abstract) M463.
13. Betteridge JD, Gibson M. on behalf of the ANDROMEDA study investigators Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes: results of the ANDROMEDA study. 74th European Atherosclerosis Society Congress. Atherosclerosis 2004; 5 (Suppl 1): 107-8, (Abstract) M464.
14. Franken AAM, Wolffenbuttel BHR, Vincent HH. on behalf of the Dutch CORALL Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes. 74th European Atherosclerosis Society Congress. Atherosclerosis 2004; 5 (Suppl 1): 118, (Abstract) M513.
15. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.
16. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511.
17. Modan M, Karasik A, Halkin H, et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin- dependent) diabetes and on insulin response. The Israel study of glucose intolerance, obesity and hypertension. Diabetologia 1986; 29: 82-9.
18. Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 2000; 49: 2094-101.
19. Reaven GM. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism 1992; 41 (5 Suppl. 1): 16-9.
20. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 1999; 84 (1A): 11J-14J.
21. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992; 12: 1496-502.
22. Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol 1982; 115: 657-63.
23. Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Invest 1999; 29 (Suppl. 2): 12-6.
24. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998; 316: 823-8.
25. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
26. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995; 75: 1196-201.
27. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255: 188-205.
28. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
29. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276: 875-81.
30. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-8.
31. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 69-75.
32. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
33. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-80.
34. Moro E, Alessandrini P, Zambon C, et al. Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition? Diabet Med 1999; 16: 663-9.
35. Fukagawa NK, Anderson JW, Hageman G, Young VR, Minaker KT. High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. Am J Clin Nutr 1990; 52: 524-8.
36. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 2001; 135: 447-59.
37. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes, the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.
38. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
39. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular event and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol and Recurrent Events (CARE) trial. Circulation 1998; 98: 2513-9.
40. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
41. Colhoun HM, Thomason MJ, Mackness MI, et al. Collaborative AtoRvastatin Diabetes Study (CARDS). Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med 2002; 19: 201-11.
42. Colhoun HM, Betteridge DJ, Durrington PN, et al.. Effectiveness of Lipid Lowering for the Primary Prevention of Major Cardiovascular Events in Diabetes. American Diabetes Association 64th Scientific Sessions Abstract 15-LB. Available at: http://www.diabetes.org/am04/.
43. Colhoun H, Betteridge J, Durrington P, et al. on behalf of the CARDS Investigators. Collaborative Atorvastatin Diabetes Study (CARDS). Presentation from the American College of Cardiology 50th Scientific Session. Available at: http://www.cardstrial.org/docs/007%20FINAL%20SLIDES%20FOR%20WEBCAST%2001: 20030604ppt
44. Gmerek A, Mclain R, Nawrocki J. A 4-year, placebo-controlled study of atorvastatin as prevention of CHD endpoints in patients with non-insulin dependent diabetes mellitus. Diabetes 1997; 47: A363.
45. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
46. LaRosa JC. Reduction of serum LDL-C levels: a relationship to clinical benefits. Am J Cardiovasc Drugs 2003; 3: 271-81.
47. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
48. Hoogwerf BJ, Waness A, Cressman M, et al. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes 1999; 48: 1289-94.
49. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 2004; 291: 1071-80.
50. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25: 1198-202.
51. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345: 1583-92.
52. Bays HE, Dujovne CA, McGovern ME et al. ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation. Comparison of once-daily, niacin extended-release/ lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003; 91: 667-72.
53. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract 2004; 64: 137-51.
54. Brunzell JD, Ayyobi AF. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. Am J Med 2003; 115 (Suppl. 8A): 24S-28S.
55. Morse JS, Brown BG, Zhao XQ. Niacin Plus Simvastatin Protect Against Atherosclerosis Progression and Clinical Events in CAD Patients with Low HDL-C and Diabetes Mellitus or Impaired Fasting Glucose. American College of Cardiology 50th Scientific Session. 2001: Abstract 842-3.
56. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002; 86: 5-18.
57. Sheu WH, Chen YT, Lee WJ. Improvement in endothelial dysfunction with LDL cholesterol level < 80 mg/dl in type 2 diabetic patients. Diabetes Care 2001; 24: 1499-501.
58. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 2004; 18: 805-15.
59. Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28: 573-9.
60. Tan KC, Ai VH, Chow WS, Chau MT, Leong L, Lam KS. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 3212-6.
61. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet 1993; 341: 1496-500.
62. Davis ME, Harrison DG. Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating endothelial cell nitric oxide production. Circulation 2001; 103: 2-4.
63. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial Superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-9.
64. Kolyada AY, Fedtsov A, Madias NE. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells. Hypertension 2001; 38: 1024-9.
65. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase Inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-7.
66. van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C; DALI-Study Group. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-35.
67. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
68. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol Recurrent Events (CARE) Invest Circulation 1999; 100: 230-5.
69. Sonmez A, Baykal Y, Kilic M, et al. Fluvastatin improves insulin resistance in nondiabetic dyslipidemic patients. Endocrine 2003; 22: 151-4.
70. Costa A, Casamitjana R, Casals E, et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Meet 2003; 20: 743-5.
71. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of Diabetes Mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 2001: 357-62.
72. Paniagua JA, Lopez-Miranda J, Escribano A, et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. Diabetes 2002; 51: 2596-603.
73. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344 (8934): 1383-9.
74. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. lancet 2002; 360: 7-22.
75. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002; 56: 1-11.
76. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002; 53: 493-502.
77. Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on Microvascular outcomes. J Diabetes Complications 2001; 15: 113-9.
78. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-9.
79. Tonolo G, Ciccarese M, Brizzi P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997; 20: 1891-5.
80. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38 (5): 604-9.
81. Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH. Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. Diabetes Care 2003; 26: 1796-801.
82. Grover SA, Coupai L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000; 102: 722-7.
83. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287: 2542-51.
84. Hippisley-Cox J, Cater R, Pringle M, Coupland C. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 2003; 326: 689.
85. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111: 185-91.
86. Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003; 20: 303-28.
87. Schuster H. Rosuvastatin - a highly effective new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiol 2003; 99: 126-39.
88. McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-98.
89. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-60.
90. Hunninghake DB, Stein EA, Bays HE, et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis 2004; 15: 115-23.
91. Blasetto JW, Stein EA, Brown V, et al. Efficacy of rosuvastatin compared with other statin at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003; 91 (Suppl.): 3C-10C.
92. Ballantyne CM, Stein EA, Paoletti R, Southworth H, Blasetto JW. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 2003; 91: 25C-27C.
93. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003; 91: 11C-17C.
94. Schuster H, Barter PJ, Stender S, et al. Effective Reductions in Cholesterol Using Rosuvastatin Therapy I Study Group. Effects of switching statins on achievement of lipid goals: measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-12.
95. Schuster H, Barter PJ, Stender S, et al. Effects of rosuvastatin and atorvastatin on plasma lipids in type 2 diabetes patients in the MERCURY I study. 40th Annual Meeting of the European Association for the Study of Diabetes (EASD). Diabetologia 2004, in press.
96. Schuster H, Fox JC. Investigating cardiovascular risk reduction - the Rosuvastatin GALAXY Programme trademark. Expert Opin Pharmacother 2004; 5: 1187-200.
97. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004; 102: 52-60.
98. Ridker PM, JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108: 2292-7.